Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium‐sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA....

Descripción completa

Detalles Bibliográficos
Autores principales: van der Geest, Kornelis S. M., Sandovici, Maria, van Sleen, Yannick, Sanders, Jan‐Stephan, Bos, Nicolaas A., Abdulahad, Wayel H., Stegeman, Coen A., Heeringa, Peter, Rutgers, Abraham, Kallenberg, Cees G. M., Boots, Annemieke M. H., Brouwer, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Special Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175064/
https://www.ncbi.nlm.nih.gov/pubmed/29648680
http://dx.doi.org/10.1002/art.40520
Descripción
Sumario:Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium‐sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long‐term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.

Ejemplares similares